Home Newsfeeds Japan Approves Plan to Revive Nuclear Energy to Avert Crisis

News

Japan Approves Plan to Revive Nuclear Energy to Avert Crisis

https://www.ft.com/content/721b66c6-fd73-432f-aef9-fe59befba2cf

byCharles Gross

December 22, 2022

1 minute read

https://www.ft.com/content/721b66c6-fd73-432f-aef9-fe59befba2cf

FDA
News

Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland

By Charles Gross

December 10, 1:45 PM

Belite Bio, Inc (NASDAQ:BLTE), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs,

BLTE

Piper Sandler Maintains Overweight on Albemarle, Raises Price Target to $330

By Benzinga Newsdesk

February 21, 9:17 AM

Piper Sandler analyst Charles Neivert maintains Albemarle (NYSE:ALB) with a Overweight and raises the price target from $310 to $330.

ALB

Levi Strauss Gears Up For Q3 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

By Lisa Levin

October 5, 10:31 AM

Levi Strauss & Co. (NYSE: LEVI) is expected to release financial results for the third quarter ended Aug. 27, 2023, after the closing bell on Oct. 5, 2023.

LEVI

CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved

By Benzinga Newsdesk

April 24, 8:08 AM

Full target enrollment of 216 patients achieved Topline data from CARPO expected in 2Q 2024 LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage

CALC

Japan Approves Plan to Revive Nuclear Energy to Avert Crisis

Related Posts

Belite Bio Received Approval To Initiate Tinlarebant Phase 3 Clinical Trial For GA in Switzerland

Piper Sandler Maintains Overweight on Albemarle, Raises Price Target to $330

Levi Strauss Gears Up For Q3 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

CalciMedica Announces Last Patient Enrolled In Phase 2b CARPO Trial Of Auxora In Acute Pancreatitis; Full Target Enrollment Of 216 Patients Achieved